C-N4KMAptah Bio
RNA therapeutics, transcription modulation, U1 snRNP
repairingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-N4KM
C-N4KMC-N4KMRNA therapeutics, transcription modulation, U1 snRNP
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Aptah states that it is a biotech company focused on designing molecules that can control cell biology without altering DNA, with the goal of supporting medical advancements by bringing innovative technology into drug discovery. It argues that drug development is too slow, expensive, and failure-prone, and says its algorithm can identify the best compound in record time to reduce time, cost, and risk while improving preclinical and clinical testing. The company also says its antisense technology works by modulating pre-mRNA so a patient’s own cells can produce the exact proteins needed to help prevent, treat, or cure disease, with a stated focus on neglected diseases with high mortality and occurrence.
SourceAptah Biosciences states that it aims to revolutionize how diseases are diagnosed and treated by introducing innovative technologies into drug discovery. The company says its core belief is that modulating spliceosome machinery and pre-mRNA can precisely control transcription and specific gene expression, including not just silencing but editing pre-mRNA, and that controlling TAU expression inside cells can restore it to normal levels and thereby stabilize cellular metabolism while reducing oxidation, inflammation, and reproduction rate in diseases associated with abnormal tau protein.
SourceAptah Bio states that many genetic disorders involve splicing mutations and that the spliceosome can be harnessed therapeutically to correct aberrant RNA splicing and other post-transcriptional processes. The company presents its ASMO platform as a way to go beyond gene-expression suppression by restoring and reprogramming RNA-protein interactions, precisely controlling gene expression, and addressing diseases caused by gene dysregulation, especially neurodegenerative disorders.
SourceAptah states that cancer and neurodegenerative diseases can be addressed through novel RNA therapies built on its ASMO platform, which is designed to modulate rather than silence specific snRNPs/RNA-binding proteins involved in protein aggregation, protein synthesis, autophagy, organelle transport, cell proliferation, growth, migration, and synaptic function.
Source